Araris’ platform technology links highly potent cytotoxic agents to off-the-shelf antibodies, thus forming Antibody-Drug-Conjugates (ADCs). This enables the highly-selective delivery of highly effective drugs to the target tissue. Up to now, ADCs have faced challenges in manufacturing, stability and poor bioavailability leading to toxicity, lack of efficacy and drug resistance. Araris’ proprietary linker technology and conjugation method addresses these major short-comings. Its approach has the potential to drastically simplify and accelerate ADC development, manufacturing, to improve performance, and to widen options for treatment modalities and also to significantly improve safety and tolerability in patients.